Skip to content

Conventionally Fractionated Re-irradiation for Recurrent Ependymoma.

Sep 2026 · Neuro-Oncology · 1 citation · 25 references
Medicine

TL;DR

A second course of conventionally fractionated radiotherapy can extend survival in recurrent pediatric ependymoma, but prognosis remains poor, especially for those with combined local and distant failure or adverse features.

Abstract

Background

Reirradiation is used for children and adolescents with recurrent ependymoma after prior surgery and focal irradiation. This study assessed the long-term benefits and risks of a second course of fractionated radiotherapy, patient selection, factors associated with progression-free survival (PFS) and overall survival (OS), and the role of craniospinal irradiation (CSI) at first recurrence.

Methods

From July 1994 to January 2024, 150 pediatric ependymoma patients at St. Jude Children's Research Hospital received a second course of fractionated radiotherapy. Sixty-four were enrolled in a prospective trial. Inclusion required conventional fractionation (≥50.4Gy) for both courses, with CSI for metastatic disease. Kaplan-Meier estimates measured PFS and OS, Cox models assessed associations with covariates, and competing risks analysis evaluated necrosis and death from complications.

Results

At 10 and 20 years, PFS/OS for the cohort were 19.5%/34.3% and 9.0%/13.1%, respectively. Females had significantly better outcomes, and survival varied by initial failure pattern. No significant difference in PFS (p = 0.1351) or OS (p = 0.2705) was found between focal irradiation and CSI for patients with local failure. Necrosis was higher with proton therapy versus photons; grade 3 necrosis after reirradiation occurred in 19.9%. The 10-year cumulative incidence of death from complications or secondary tumors was 8.5%.

Conclusions

A second course of conventionally fractionated radiotherapy can extend survival in recurrent pediatric ependymoma, but prognosis remains poor, especially for those with combined local and distant failure or adverse features. CSI did not improve outcomes for local failures. Proton therapy increased necrosis risk, emphasizing the need for careful selection and follow-up.

View source

Similar papers

Open access Aug 2026

152 Re-irradiation for recurrent paediatric diffuse midline glioma: an international, multi-institutional retrospective study

In this large, multi-institutional international cohort, children with DMG treated with re-irradiation at progression showed a survival benefit, supporting re-irradiation as a key component of salvage therapy.

A. Alex, Sean Hasson, Helen Benghiat et al. · 0 citations
Sep 2026

Long-term outcomes after adjuvant radiotherapy in adult spinal ependymomas: a multicenter study by the trod Neuro-Oncology research group (07 − 005)

While GTR remains the gold standard for long-term prognosis, adjuvant RT provides effective LC in Grade 2 SE patients with residual disease, and early adjuvant RT (within 1.5 months post-surgery) is a critical management strategy for non-GTR cases.

E. Senturk, P. Erpolat, S. Kamer et al. · 0 citations
Open access Oct 2026

Multifocal Glioblastoma Managed With Primary Temozolomide as a Strategy to Delay Radiation Therapy: Clinical and Radiological Outcomes.

AIM To evaluate the clinical and radiological outcomes of upfront temozolomide (TMZ) monotherapy in deferring radiotherapy for multifocal glioblastoma (GBM). METHODS We analysed 18 consecutive adult patients with newly diagnosed, multifocal GBM treated with upfront TMZ monotherapy between 2016 and 2024. The primary e...

Chun Khai Loh, H. Wheeler, Adrian Lee et al. · 0 citations
Clinical trial Open access Sep 2026

Clinical outcomes after reirradiation with dose painting of recurrent or second primary head and neck cancer

Purpose Recurrent or second primary head and neck cancer (rsHNC) presents a radiotherapeutic challenge due to limited tolerance of previously irradiated tissues. These patients could benefit from dose painting (DP), which focuses on delivering maximal dose to areas of high tumor burden while respecting dose constraints...

E. Dale, M. Evensen, C. D. Amdal et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.